Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat
in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Michael Millward; T Price; A Townsend; C Sweeney; A Spencer; S Sukumaran; A Longenecker; L Lee; A Lay; G Sharma; R.M Gemmill; H.A Drabkin; G.K Lloyd; S.T.C Neuteboom; D.J Mcconkey; M.A Palladino; M.A Spear

doi:10.1007/s10637-011-9766-6

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Michael Millward, T Price, A Townsend, C Sweeney, A Spencer, S Sukumaran, A Longenecker, L Lee, A Lay, G Sharma, R.M Gemmill, H.A Drabkin, G.K Lloyd, S.T.C Neuteboom, D.J Mcconkey, M.A Palladino, M.A Spear

Research output: Contribution to journal › Article › peer-review

113 Citations (Scopus)

Original language	English
Pages (from-to)	2303–2317
Journal	Investigational New Drugs
Volume	30
DOIs	https://doi.org/10.1007/s10637-011-9766-6
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10637-011-9766-6

Cite this

Millward, M., Price, T., Townsend, A., Sweeney, C., Spencer, A., Sukumaran, S., Longenecker, A., Lee, L., Lay, A., Sharma, G., Gemmill, R. M., Drabkin, H. A., Lloyd, G. K., Neuteboom, S. T. C., Mcconkey, D. J., Palladino, M. A., & Spear, M. A. (2012). Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs, 30, 2303–2317. https://doi.org/10.1007/s10637-011-9766-6

@article{9da6d03648784ba2bfcd9efc1787e8bd,

title = "Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination",

author = "Michael Millward and T Price and A Townsend and C Sweeney and A Spencer and S Sukumaran and A Longenecker and L Lee and A Lay and G Sharma and R.M Gemmill and H.A Drabkin and G.K Lloyd and S.T.C Neuteboom and D.J Mcconkey and M.A Palladino and M.A Spear",

year = "2012",

doi = "10.1007/s10637-011-9766-6",

language = "English",

volume = "30",

pages = "2303–2317",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

}

Millward, M, Price, T, Townsend, A, Sweeney, C, Spencer, A, Sukumaran, S, Longenecker, A, Lee, L, Lay, A, Sharma, G, Gemmill, RM, Drabkin, HA, Lloyd, GK, Neuteboom, STC, Mcconkey, DJ, Palladino, MA & Spear, MA 2012, 'Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination', Investigational New Drugs, vol. 30, pp. 2303–2317. https://doi.org/10.1007/s10637-011-9766-6

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. / Millward, Michael; Price, T; Townsend, A et al.

In: Investigational New Drugs, Vol. 30, 2012, p. 2303–2317.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

AU - Millward, Michael

AU - Price, T

AU - Townsend, A

AU - Sweeney, C

AU - Spencer, A

AU - Sukumaran, S

AU - Longenecker, A

AU - Lee, L

AU - Lay, A

AU - Sharma, G

AU - Gemmill, R.M

AU - Drabkin, H.A

AU - Lloyd, G.K

AU - Neuteboom, S.T.C

AU - Mcconkey, D.J

AU - Palladino, M.A

AU - Spear, M.A

PY - 2012

Y1 - 2012

U2 - 10.1007/s10637-011-9766-6

DO - 10.1007/s10637-011-9766-6

M3 - Article

C2 - 22080430

VL - 30

SP - 2303

EP - 2317

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

ER -

Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs. 2012;30:2303–2317. https://doi.org/10.1007/s10637-011-9766-6